Medtronic (MDT)

It doesn't get much more dependable and lucrative than the healthcare industry.

The company dominates the robotic surgery market.

I focus on well-run companies that pay reliable dividends; a bull or bear market doesn't change how well a company is run.

Don't wait until they recover to initiate positions.

The stocks on this list offer above-average yields and aren't volatile investments.

It could be a great move by the billionaire hedge fund manager.

They have a habit of consistently raising their payouts.

Analysts remain relatively more upbeat, but this could prove fleeting.

Even the hottest AI stocks won't win forever. Diversification is the key to long-term wealth.

Medtronic recently reported strong results, highlighting impressive growth.

The most recent research report on the "Endoscopy Equipment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Medtronic wants a bite of the robotics-assisted surgery market, which could swell to over $63 billion over the next decade.

These stocks pay between 2.3% and 3.5% in dividends.

BTIG upgrades Medtronic (MDT) to Buy with a $90 target after a strong Q4 revenue beat and accelerating organic growth. Read more.

Medtronic is on track to reverse after a major market meltdown driven by fear. The upside potential is double-digit, not including the dividend.

Medtronic (MDT) Q4 2026 Earnings Transcript

The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

Medtronic just wrapped up its best year in a decade.

Medtronic has undergone a business revamp and is now ready to grow again, including by leaning into acquisitions.

Medtronic (MDT) stock jumps after beating Q4 revenue expectations, driven by strong growth in cardiovascular and diabetes tech.

Medtronic (NYSE:MDT) reported what executives described as its strongest top-line performance in a decade, as growth in cardiac ablation, diabetes, medical-surgical products and select neuroscience platforms helped drive fiscal fourth-quarter and full-year results above expectations. Chairman and C